These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 28992560)

  • 21. Clinical experience on the use of perampanel in epilepsy among child neurologists in the Philippines.
    Macrohon B; Janette Resurreccion-De La Calzada J; Sanchez-Gan B
    Brain Dev; 2021 Mar; 43(3):411-418. PubMed ID: 33272774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy.
    Tsai JJ; Ikeda A; Hong SB; Likasitwattanakul S; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():37-46. PubMed ID: 30869165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
    Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
    Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability.
    Garamendi-Ruiz I; García-García ME; Bertol-Alegre V; Mauri-Llerda JÁ; García-Morales I; Garayoa-Irigoyen V; Agúndez-Sarasola M; De Toledo-Heras M; García-Morales V; García-Gomara MJ; Arcos-Sánchez C; Gago-Veiga A; Escalza-Cortina I; Rueda-Mena E; Muñoz-Fargas E; Santos-Lasaosa S; Oliván-Usieto JA; Julián LD; Gómez-Esteban JC; Marinas-Alejo A
    Epileptic Disord; 2016 Jun; 18(2):173-80. PubMed ID: 27238234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years.
    Ikemoto S; Hamano SI; Hirata Y; Matsuura R; Koichihara R
    Seizure; 2019 Dec; 73():75-78. PubMed ID: 31759296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
    Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
    Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures.
    Gil-López FJ; Montoya J; Falip M; Aparicio J; López-González FJ; Toledano R; Gil-Nagel A; Molins A; García I; Serrano P; Domenech G; Torres F; Donaire A; Carreño M
    Acta Neurol Scand; 2018 Aug; 138(2):122-129. PubMed ID: 29573400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of perampanel in Chinese paediatric patients (2-14 years) with refractory epilepsy: a retrospective, observational study.
    Qu R; Dai Y; Chen X; Li R; Liu M; Zhu Y
    Epileptic Disord; 2021 Dec; 23(6):854-864. PubMed ID: 34730518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
    Gidal BE; Ferry J; Majid O; Hussein Z
    Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perampanel as add-on treatment in refractory focal epilepsy. The Dianalund experience.
    Juhl S; Rubboli G
    Acta Neurol Scand; 2016 Nov; 134(5):374-377. PubMed ID: 26763771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
    Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment.
    Huber B; Schmid G
    Epilepsy Behav; 2017 Jan; 66():74-79. PubMed ID: 28038390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved irritability, mood, and quality of life following introduction of perampanel as late adjunctive treatment for epilepsy.
    Moraes JS; Hepworth G; Ignatiadis S; Dharan A; Carne R; Seneviratne U; Cook MJ; D'Souza WJ
    Epilepsy Behav; 2020 Mar; 104(Pt A):106883. PubMed ID: 32045874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.
    Rohracher A; Höfler J; Kalss G; Leitinger M; Kuchukhidze G; Deak I; Dobesberger J; Novak H; Pilz G; Zerbs A; Trinka E
    Epilepsy Behav; 2015 Aug; 49():354-8. PubMed ID: 25962657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.
    Krauss GL; Serratosa JM; Villanueva V; Endziniene M; Hong Z; French J; Yang H; Squillacote D; Edwards HB; Zhu J; Laurenza A
    Neurology; 2012 May; 78(18):1408-15. PubMed ID: 22517103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.
    Tsai JJ; Wu T; Leung H; Desudchit T; Tiamkao S; Lim KS; Dash A
    Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations.
    Vecht C; Duran-Peña A; Houillier C; Durand T; Capelle L; Huberfeld G
    J Neurooncol; 2017 Jul; 133(3):603-607. PubMed ID: 28492978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and tolerability of adjunctive perampanel in pediatric patients (aged 4-12 years) with refractory epilepsy: An observational study.
    Chu SJ; Li Y; Tang JH
    Medicine (Baltimore); 2022 Nov; 101(45):e31408. PubMed ID: 36397377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of perampanel in children with refractory epilepsy of genetic aetiology.
    Qu R; Dai Y; Qu X; Li Y; Shao X; Zhou R; Zhu Y; Chen X
    Epileptic Disord; 2022 Aug; 24(4):687-695. PubMed ID: 35770768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.